Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy
Background and Purpose: The tumor immune microenvironment (TIME) of breast cancer with positive human epidermal growth factor receptor 2 (HER2) is significantly related to the efficacy of trastuzumab, indicating the clinical potential of immunocheckpoint therapy combined with trastuzumab. This study...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2023-05-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1686896442431-1211872650.pdf |